NDA 022393 · Bristol-Myers
Istodax
Romidepsin · Intravenous
NovelAccelerated approvalOrphanLast checked: Nov 20, 2026Latest source record: Jul 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Nov 5, 2009
Approved uses
4
Original approval plus efficacy supplements
Registered trials
100
5 Phase 3, 3 recruiting
FAERS reports
1,689
1,456 serious, 447 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 31, 2023.
ISTODAX is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).
Mechanism: Romidepsin is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression. HDACs also deacetylate non-histone proteins, such as transcription factors. In vitro, romidepsin causes the accumulation of acetylated histones, and induces cell cycle arrest and apoptosis of some cancer cell lines with IC 50 values in the nanomolar range. The mechanism of the antineoplastic effect of romidepsin observed in nonclinical and clinical studies has not been fully characterized.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 30, 2021 Supplement 17 · Efficacy OrphanLetterLabel
- Oct 15, 2014 Supplement 13 · Efficacy LabelLetter
- Jun 16, 2011 Supplement 4 · Efficacy · priority review Accelerated approvalLabelLetter
- Nov 5, 2009 Original approval · Type 1 - New Molecular Entity NovelOrphanLabelReviewSummary Review
1 products under this application
- ISTODAX · ROMIDEPSIN 10MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Romidepsin" as an intervention, any sponsor and status, largest first.
- Emodepside Phase II Trial for Treatment of OnchocerciasisPivotal-lookingStatus unknown
Drugs for Neglected DiseasesAcademic, hospital or other
NCT05180461 · 578 participants (planned) · Start Aug 30, 2021 · Primary completion Sep 18, 2026
Drug: emodepside; matching placebo of emodepside and 2 more · For: Onchocerciasis
Sites: Kimpese, Democratic Republic of the Congo; Masi-Manimba, Democratic Republic of the Congo; Hohoe, Ghana
- Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaPivotal-lookingCompleted
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT01796002 · 421 participants · Start Jan 2013 · Primary completion Dec 13, 2019
Drug: Romidepsin + CHOP; CHOP · For: Peripheral T-cell Lymphoma
Sites: Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium · 131 sites in all
- Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell LymphomaPivotal-lookingCompleted
Millennium Pharmaceuticals, Inc.Takeda (TAK)
NCT01482962 · 271 participants · Start Jun 11, 2012 · Primary completion Jun 30, 2015
Drug: Alisertib; Pralatrexate and 2 more · For: Relapsed Peripheral T-Cell Lymphoma; Refractory Peripheral T-Cell Lymphoma
Sites: Birmingham, Alabama; La Jolla, California; Orlando, Florida · 151 sites in all
- Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for LymphomaPivotal-lookingRecruiting
University of VirginiaAcademic, hospital or other
NCT03161223 · 148 participants (planned) · Start May 30, 2018 · Primary completion Feb 2023
Drug: Durvalumab; Pralatrexate and 2 more · For: Lymphoma, T-Cell
Sites: Charlottesville, Virginia
CelgeneBristol Myers Squibb (BMY)
NCT00426764 · 131 participants · Start Jun 19, 2007 · Primary completion Nov 11, 2010
Drug: Romidepsin · For: Peripheral T-cell Lymphoma
Sites: La Jolla, California; Los Angeles, California; San Francisco, California · 90 sites in all
- Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell LymphomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00007345 · 131 participants · Start Mar 8, 2001 · Primary completion Jan 26, 2015
Drug: Romidepsin · For: Cutaneous T Cell Lymphoma; Peripheral T Cell Lymphoma
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Duarte, California · 13 sites in all
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT02783625 · 114 participants · Start May 23, 2016 · Primary completion Apr 21, 2026
Drug: Romidepsin; Bortezomib and 1 more · For: Lymphoma; Relapsed/Refractory T-cell Lymphomas
Sites: Stanford, California; Boston, Massachusetts; St Louis, Missouri · 11 sites in all
CelgeneBristol Myers Squibb (BMY)
NCT00106431 · 102 participants · Start Jan 1, 2005 · Primary completion Jun 1, 2008
Drug: romidepsin (depsipeptide, FK228) · For: Cutaneous T-cell Lymphoma
Sites: Los Angeles, California; Stanford, California; Boston, Massachusetts · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death126
- nausea124
- thrombocytopenia120
- peripheral t-cell lymphoma unspecified118
- pyrexia105
- drug ineffective91
- anaemia80
- fatigue80
- vomiting78
- platelet count decreased74
- electrocardiogram qt prolonged71
- disease progression66
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 39 |
| 2011 | 48 |
| 2012 | 67 |
| 2013 | 83 |
| 2014 | 74 |
| 2015 | 129 |
| 2016 | 128 |
| 2017 | 76 |
| 2018 | 124 |
| 2019 | 186 |
| 2020 | 132 |
| 2021 | 108 |
| 2022 | 174 |
| 2023 | 68 |
| 2024 | 113 |
| 2025 | 87 |
| 2026 | 53 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Istodax* (Romidepsin*) · HCPCS J9319
2024 spending
$25.5M
Beneficiaries
339
3,031 claims
Per beneficiary
$75,142
2024 ASP limit $30.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $6,417,223 |
| 2022 | $25,612,146 |
| 2023 | $27,982,716 |
| 2024 | $25,473,023 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial.
Horwitz SM, Nirmal AJ, Rahman J, et al. · Nat Med 2024 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study.
Falchi L, Ma H, Klein S, et al. · Blood 2021 · Clinical Trial, Phase II, Multicenter Study
- Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study.
Dupuis J, Bachy E, Morschhauser F, et al. · Lancet Haematol 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Pralatrexate pharmacology and clinical development.
Marchi E, Mangone M, Zullo K, et al. · Clin Cancer Res 2013 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, et al. · J Clin Oncol 2022 · Clinical Trial, Phase III, Comparative Study
- Maintenance therapy with romidepsin after autologous stem-cell transplant for peripheral T-cell lymphoma.
Khan N, Dahi PB, Khimani F, et al. · Blood Adv 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.